These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 28770102)

  • 1. A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine.
    Kalloger SE; Riazy M; Tessier-Cloutier B; Karasinska JM; Gao D; Peixoto RD; Samimi S; Chow C; Wong HL; Mackey JR; Renouf DJ; Schaeffer DF
    J Pathol Clin Res; 2017 Jul; 3(3):179-190. PubMed ID: 28770102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concordance of human equilibrative nucleoside transporter-1 expressions between murine (10D7G2) and rabbit (SP120) antibodies and association with clinical outcomes of adjuvant chemotherapy for pancreatic cancer: A collaborative study from the JASPAC 01 trial.
    Okamura Y; Boku N; Ghaneh P; Greenhalf W; Yasukawa S; Narimatsu H; Fukutomi A; Konishi M; Morinaga S; Toyama H; Maeda A; Shimizu Y; Nakamori S; Sata N; Yamakita K; Takahashi A; Takayama W; Yamaguchi R; Tomikawa M; Yanagisawa A; Neoptolemos JP; Uesaka K
    Cancer Rep (Hoboken); 2022 May; 5(5):e1507. PubMed ID: 34327872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status.
    Raffenne J; Nicolle R; Puleo F; Le Corre D; Boyez C; Marechal R; Emile JF; Demetter P; Bardier A; Laurent-Puig P; de Mestier L; Paradis V; Couvelard A; VanLathem JL; MacKey JR; Bachet JB; Svrcek M; Cros J
    Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31752123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: a comparison between murine and rabbit antibodies.
    Svrcek M; Cros J; Maréchal R; Bachet JB; Fléjou JF; Demetter P
    Histopathology; 2015 Feb; 66(3):457-62. PubMed ID: 25298108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and predictive value of human equilibrative nucleoside transporter 1 (hENT1) in extrahepatic cholangiocarcinoma: a translational study.
    Boyd LNC; Nooijen LE; Ali M; Puik JR; Moustaquim J; Fraga Rodrigues SM; Broos R; Belkouz A; Meijer LL; Le Large TYS; Erdmann JI; Hooijer GKJ; Heger M; Van Laarhoven HWM; Roos E; Kazemier G; Giovannetti E; Verheij J; Klümpen HJ
    Front Pharmacol; 2023; 14():1274692. PubMed ID: 37920204
    [No Abstract]   [Full Text] [Related]  

  • 6. Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody.
    Ormanns S; Heinemann V; Raponi M; Isaacson J; Laubender RP; Haas M; Kruger S; Kleespies A; Mann E; Bartosiewicz M; Kirchner T; Boeck S
    Eur J Cancer; 2014 Jul; 50(11):1891-9. PubMed ID: 24857044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial.
    Sinn M; Riess H; Sinn BV; Stieler JM; Pelzer U; Striefler JK; Oettle H; Bahra M; Denkert C; Bläker H; Lohneis P
    Eur J Cancer; 2015 Aug; 51(12):1546-54. PubMed ID: 26049689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy.
    Bird NT; Elmasry M; Jones R; Psarelli E; Dodd J; Malik H; Greenhalf W; Kitteringham N; Ghaneh P; Neoptolemos JP; Palmer D
    Br J Surg; 2017 Mar; 104(4):328-336. PubMed ID: 28199010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.
    Greenhalf W; Ghaneh P; Neoptolemos JP; Palmer DH; Cox TF; Lamb RF; Garner E; Campbell F; Mackey JR; Costello E; Moore MJ; Valle JW; McDonald AC; Carter R; Tebbutt NC; Goldstein D; Shannon J; Dervenis C; Glimelius B; Deakin M; Charnley RM; Lacaine F; Scarfe AG; Middleton MR; Anthoney A; Halloran CM; Mayerle J; Oláh A; Jackson R; Rawcliffe CL; Scarpa A; Bassi C; Büchler MW;
    J Natl Cancer Inst; 2014 Jan; 106(1):djt347. PubMed ID: 24301456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive and Prognostic Properties of Human Equilibrative Nucleoside Transporter 1 Expression in Gemcitabine-Treated Pancreatobiliary Cancer: A Meta-Analysis.
    Vos LJ; Yusuf D; Lui A; Abdelaziz Z; Ghosh S; Spratlin JL; Mackey JR
    JCO Precis Oncol; 2019 Dec; 3():1-22. PubMed ID: 35100740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy.
    Morinaga S; Nakamura Y; Watanabe T; Mikayama H; Tamagawa H; Yamamoto N; Shiozawa M; Akaike M; Ohkawa S; Kameda Y; Miyagi Y
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S558-64. PubMed ID: 21913012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic and predictive role of class III β-Tubulin and hENT1 expression in patients with advanced pancreatic ductal adenocarcinoma.
    Sahin TK; Isik A; Guven DC; Ceylan F; Babaoglu B; Akyol A; Yalcin S; Dizdar O
    Pancreatology; 2024 Mar; 24(2):279-288. PubMed ID: 38272717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.
    Farrell JJ; Elsaleh H; Garcia M; Lai R; Ammar A; Regine WF; Abrams R; Benson AB; Macdonald J; Cass CE; Dicker AP; Mackey JR
    Gastroenterology; 2009 Jan; 136(1):187-95. PubMed ID: 18992248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.
    Spratlin J; Sangha R; Glubrecht D; Dabbagh L; Young JD; Dumontet C; Cass C; Lai R; Mackey JR
    Clin Cancer Res; 2004 Oct; 10(20):6956-61. PubMed ID: 15501974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Clinical Response and Survival in the Patients With Pancreatic Ductal Adenocarcinoma Undergoing Gemcitabine-Based Chemoradiotherapy.
    Yamada R; Mizuno S; Uchida K; Yoneda M; Kanayama K; Inoue H; Murata Y; Kuriyama N; Kishiwada M; Usui M; Ii N; Tsuboi J; Tano S; Hamada Y; Tanaka K; Horiki N; Ogura T; Shiraishi T; Takei Y; Katayama N; Isaji S
    Pancreas; 2016; 45(5):761-71. PubMed ID: 26784908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A biomarker stratified prospective trial.
    Shin DW; Lee JC; Kim J; Yoon YS; Han HS; Kim H; Hwang JH
    Pancreatology; 2021 Jun; 21(4):796-804. PubMed ID: 33795193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine.
    Kawada N; Uehara H; Katayama K; Nakamura S; Takahashi H; Ohigashi H; Ishikawa O; Nagata S; Tomita Y
    J Hepatobiliary Pancreat Sci; 2012 Nov; 19(6):717-22. PubMed ID: 22426593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human equilibrative nucleoside transporter-1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression; do they have survival impact to pancreatic cancer?
    Hwang DW; Shin E; Cho JY; Han HS; Yoon YS
    Ann Hepatobiliary Pancreat Surg; 2020 May; 24(2):127-136. PubMed ID: 32457256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma.
    Perera S; Jang GH; Wang Y; Kelly D; Allen M; Zhang A; Denroche RE; Dodd A; Ramotar S; Hutchinson S; Tehfe M; Ramjeesingh R; Biagi J; Lam B; Wilson J; Fischer SE; Zogopoulos G; Notta F; Gallinger S; Grant RC; Knox JJ; O'Kane GM
    Clin Cancer Res; 2022 Dec; 28(23):5115-5120. PubMed ID: 36222851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy.
    Murata Y; Hamada T; Kishiwada M; Ohsawa I; Mizuno S; Usui M; Sakurai H; Tabata M; Ii N; Inoue H; Shiraishi T; Isaji S
    J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):413-25. PubMed ID: 21898089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.